Relapsed and/or Refractory Multiple Myeloma (RRMM)
Oncology
Prevalence
17.0 / 100K
Incidence
7.0 / 100K/yr
4 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Compare drugs
Frequently asked questions
How many drugs are in development for Relapsed and/or Refractory Multiple Myeloma (RRMM)?
BioSniper tracks 4 drugs in development for Relapsed and/or Refractory Multiple Myeloma (RRMM) across 2 companies.
How many clinical trials target Relapsed and/or Refractory Multiple Myeloma (RRMM)?
There are 1 clinical trial targeting Relapsed and/or Refractory Multiple Myeloma (RRMM) tracked by BioSniper.
What is the prevalence of Relapsed and/or Refractory Multiple Myeloma (RRMM)?
The estimated prevalence of Relapsed and/or Refractory Multiple Myeloma (RRMM) is approximately 17.0 per 100,000 population.
Deep-dive into Relapsed and/or Refractory Multiple Myeloma (RRMM)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis